Author

Sheila R. Nicewarner Peña

George Mason UniversityORCID 0009-0001-9917-577XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:metagenomics· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Adrienne D. CoxiD· 2 shared Channing J. DeriD· 2 shared Clint A. StalneckeriD· 2 shared Elisa BaldelliiD· 2 shared Jeffrey A. KlompiD· 2 shared Kirsten L. BryantiD· 2 shared Runying Y. YangiD· 2 shared Wen-Hsuan ChangiD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Adrienne D. CoxORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Concurrent AXL inhibition enhances RAS and ERK inhibitor efficacy in KRAS-mutant pancreatic and lung cancer

Yan Ming Ching, Shruthi Narayanan, Jeffrey A. Klomp, Tamara Isermann, Sina Loewe, Wen-Hsuan Chang, Andrew M. Waters, Sheila R. Nicewarner Peña, Elisa Baldelli, Cole P Martin, Teresa Börding, Runying Y. Yang, Craig M. Goodwin, Prson Gautam, Mariano Ponz‐Sarvisé, , Bjoern Papke

This study shows that combining AXL inhibition with RAS or ERK inhibitors enhances efficacy in KRAS-mutant cancers by overcoming resistance mechanisms.

bioRxiv · Aug 11, 2026 · PreprintCancer Biology

Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance

Kristina Drizyte‐Miller, Seamus E. Degan, Ryan D. Mouery, Amber M. Amparo, Brandon L. Mouery, Wen-Hsuan Chang, Runying Y. Yang, Sheila R. Nicewarner Peña, Elisa Baldelli, Jeffrey A. Klomp, Edwin J. Iwanowicz, Lee M. Graves, Emanuel F. Petricoin, Adrienne D. Cox, Clint A. Stalnecker, , Channing J. Der

This study shows that ONC201 inhibits KRAS-mutant pancreatic cancer growth and overcomes resistance to RAS inhibitors by activating ClpP and altering metabolic pathways.

bioRxiv · Dec 3, 2025 · PreprintCancer Biology